Balance Sheet: Liabilities and Stockholders’ Equity

The balance sheet provides creditors, investors, and analysts with information on company resources (assets) and its sources of capital (its equity and liabilities). It normally also provides information about the future earnings capacity of a company assets as well as an indication of cash flows that may come from receivables and inventories.

Liabilities represents obligations of a company arising from past events, the settlement of which is expected to result in an outflow of economic benefits from the entity.

Cytokinetics Inc., consolidated balance sheet: liabilities and stockholders’ equity

US$ in thousands

	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018
Accounts payable	25,611)	21,087)	8,050)	8,160)	3,764)
Clinical and preclinical costs	16,105)	13,872)	6,124)	2,215)	8,618)
Compensation related	21,767)	14,930)	11,787)	8,343)	6,118)
Other accrued expenses	6,224)	5,568)	1,404)	1,565)	1,021)
Accrued liabilities	44,096)	34,370)	19,315)	12,123)	15,757)
Current portion of term loan	—)	—)	—)	—)	2,607)
Short-term operating lease liabilities	12,829)	14,863)	2,785)	4,616)	—)
Short-term finance lease liabilities	1,000)	500)	—)	—)	—)
Other current liabilities	1,081)	1,040)	1,049)	1,124)	66)
Current liabilities	84,617)	71,860)	31,199)	26,023)	22,194)
Term loan, net, excluding current portion	63,810)	47,367)	46,209)	45,052)	39,806)
Convertible notes, net	545,808)	95,471)	89,504)	84,205)	—)
Liabilities related to revenue participation right purchase agreements, net	300,501)	179,072)	166,068)	143,276)	122,473)
Long-term deferred revenue	—)	87,000)	87,000)	—)	—)
Long-term operating lease liabilities	126,895)	112,229)	440)	2,195)	—)
Long-term finance lease liabilities	1,001)	805)	—)	—)	—)
Other non-current liabilities	43)	3,652)	—)	—)	771)
Non-current liabilities	1,038,058)	525,596)	389,221)	274,728)	163,050)
Total liabilities	1,122,675)	597,456)	420,420)	300,751)	185,244)
Preferred stock, $0.001 par value; issued and outstanding: none	—)	—)	—)	—)	—)
Common stock, $0.001 par value	94)	84)	70)	59)	55)
Additional paid-in capital	1,481,590)	1,452,268)	1,105,470)	853,341)	768,703)
Accumulated other comprehensive income (loss)	(3,590)	(869)	149)	679)	500)
Accumulated deficit	(1,585,994)	(1,207,620)	(992,306)	(865,016)	(743,324)
Stockholders’ equity (deficit)	(107,900)	243,863)	113,383)	(10,937)	25,934)
Total liabilities and stockholders’ equity (deficit)	1,014,775)	841,319)	533,803)	289,814)	211,178)

Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).

Download chart

Balance sheet item	Description	The company
Current liabilities	Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.	Cytokinetics Inc. current liabilities increased from 2020 to 2021 and from 2021 to 2022.
Non-current liabilities	Amount of obligation due after one year or beyond the normal operating cycle, if longer.	Cytokinetics Inc. non-current liabilities increased from 2020 to 2021 and from 2021 to 2022.
Total liabilities	Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.	Cytokinetics Inc. total liabilities increased from 2020 to 2021 and from 2021 to 2022.
Stockholders’ equity (deficit)	Total of all stockholders’ equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity stockholders’ equity attributable to the parent excludes the amount of stockholders’ equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.	Cytokinetics Inc. stockholders’ equity (deficit) increased from 2020 to 2021 but then decreased significantly from 2021 to 2022.

Cytokinetics Inc. (NASDAQ:CYTK)

Balance Sheet: Liabilities and Stockholders’ Equity